NASDAQ:CTSO - Cytosorbents Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cytosorbents Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.68 -0.80 (-12.35 %) (As of 02/26/2020 04:21 AM ET) Add Compare Today's Range$5.62Now: $5.68▼$6.4950-Day Range$3.81MA: $4.97▼$6.5652-Week Range$3.49Now: $5.68▼$8.48Volume478,200 shsAverage Volume376,159 shsMarket Capitalization$184.17 millionP/E RatioN/ADividend YieldN/ABeta1.67 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTSO Previous Symbol CUSIPN/A CIK1175151 Webhttp://www.cytosorbents.com/ Phone732-329-8885Debt Debt-to-Equity Ratio1.88 Current Ratio2.40 Quick Ratio2.21Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$22.50 million Price / Sales8.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book10.52Profitability EPS (Most Recent Fiscal Year)($0.56) Net Income$-17,210,000.00 Net Margins-87.79% Return on Equity-165.00% Return on Assets-68.54%Miscellaneous Employees125 Outstanding Shares32,424,000Market Cap$184.17 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive CTSO News and Ratings via Email Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CTSO Rates by TradingView Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions What is Cytosorbents' stock symbol? Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO." How were Cytosorbents' earnings last quarter? Cytosorbents Corp (NASDAQ:CTSO) released its quarterly earnings data on Tuesday, November, 5th. The medical research company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.08. The medical research company earned $6.10 million during the quarter, compared to analysts' expectations of $6.49 million. Cytosorbents had a negative return on equity of 165.00% and a negative net margin of 87.79%. View Cytosorbents' Earnings History. When is Cytosorbents' next earnings date? Cytosorbents is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Cytosorbents. What guidance has Cytosorbents issued on next quarter's earnings? Cytosorbents issued an update on its fourth quarter 2019 IntraDay earnings guidance on Tuesday, January, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $7.4-7.4 million, compared to the consensus revenue estimate of $6.71 million. What price target have analysts set for CTSO? 3 brokers have issued 1-year target prices for Cytosorbents' shares. Their forecasts range from $8.00 to $13.00. On average, they expect Cytosorbents' stock price to reach $11.00 in the next year. This suggests a possible upside of 93.7% from the stock's current price. View Analyst Price Targets for Cytosorbents. What is the consensus analysts' recommendation for Cytosorbents? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytosorbents. What are Wall Street analysts saying about Cytosorbents stock? Here are some recent quotes from research analysts about Cytosorbents stock: 1. Maxim Group analysts commented, "Cytosorbents reported 4Q18 with $5.5M in product sales, up 7% from $5.1M in 3Q18 and 30% from $4.2M y/y. For the year, revenue was $22.5M, a new record for the company and the first time revenue exceeded $20M. The company reported net income of ($5.4M) and $22.4M in cash." (3/8/2019) 2. HC Wainwright analysts commented, "We maintain our Buy rating of CytoSorbents and our 12-month price target of $15.00 per share. We derive our price target based on the average of two valuation methods: 1) price-sales multiple using 7x 2025 sales estimate discounted at 12%; and 2) price-earnings multiple using 25x 2025 earnings estimate discounted at 12%. (1) commercial; (2) partnership; (3) clinical; (4) financial; and (5) intellectual property." (3/8/2019) Has Cytosorbents been receiving favorable news coverage? Media headlines about CTSO stock have been trending positive on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cytosorbents earned a news impact score of 2.3 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Cytosorbents. Who are some of Cytosorbents' key competitors? Some companies that are related to Cytosorbents include Intersect ENT (XENT), Orthopediatrics (KIDS), Cerus (CERS), Orthofix Medical (OFIX), Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), SurModics (SRDX), SI-Bone (SIBN), AngioDynamics (ANGO), Alphatec (ATEC), MiMedx Group (MDXG), Inovio Pharmaceuticals (INO), OraSure Technologies (OSUR) and Utah Medical Products (UTMD). What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include NanoViricides (NNVC), Rekor Systems (REKR), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Micron Technology (MU), Eyepoint Pharmaceuticals (EYPT), Zynerba Pharmaceuticals (ZYNE), Aethlon Medical (AEMD), Sorrento Therapeutics (SRNE) and MEI Pharma (MEIP). Who are Cytosorbents' key executives? Cytosorbents' management team includes the folowing people: Dr. Phillip P. Chan, CEO, Pres & Director (Age 49)Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 64)Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 61)Dr. Eric R. Mortensen, Chief Medical Officer (Age 59)Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 80) Who are Cytosorbents' major shareholders? Cytosorbents' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (1.70%), Geode Capital Management LLC (1.11%), Sargent Investment Group LLC (0.82%), Sargent Investment Group LLC (0.72%), Raymond James & Associates (0.44%) and Bank of New York Mellon Corp (0.37%). Company insiders that own Cytosorbents stock include Al Kraus, Kathleen P Bloch, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents. Which major investors are selling Cytosorbents stock? CTSO stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates, Sargent Investment Group LLC, Sargent Investment Group LLC, Bradley Foster & Sargent Inc. CT, Charles Schwab Investment Management Inc., New York State Common Retirement Fund, Victory Capital Management Inc. and Bank of America Corp DE. View Insider Buying and Selling for Cytosorbents. Which major investors are buying Cytosorbents stock? CTSO stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Winning Points Advisors LLC, Goldman Sachs Group Inc., UBS Group AG, Spark Investment Management LLC, Barclays PLC, Geode Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Cytosorbents stock in the last two years include Kathleen P Bloch and Phillip P Chan. View Insider Buying and Selling for Cytosorbents. How do I buy shares of Cytosorbents? Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Cytosorbents' stock price today? One share of CTSO stock can currently be purchased for approximately $5.68. How big of a company is Cytosorbents? Cytosorbents has a market capitalization of $184.17 million and generates $22.50 million in revenue each year. The medical research company earns $-17,210,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cytosorbents employs 125 workers across the globe.View Additional Information About Cytosorbents. What is Cytosorbents' official website? The official website for Cytosorbents is http://www.cytosorbents.com/. How can I contact Cytosorbents? Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected] MarketBeat Community Rating for Cytosorbents (NASDAQ CTSO)Community Ranking: 3.5 out of 5 ( )Outperform Votes: 406 (Vote Outperform)Underperform Votes: 177 (Vote Underperform)Total Votes: 583MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/26/2020 by MarketBeat.com StaffFeatured Article: Certificate of Deposit (CD) For Risk Adverse Investors?
